Schneider Eugene 4

What Happened

• Eugene Schneider, EVP & Chief Clinical Development Officer of Ionis Pharmaceuticals, exercised 26,000 options (converted a derivative) and then sold the 26,000 shares on 2026-06-26.
• Exercise cost: $60.89 per share for a total of $1,583,140. Sale proceeds: weighted average $81.05 per share, total $2,107,196 (prices ranged $81.00–$81.34). Net cash realized before taxes/fees ≈ $524,056.
• This sequence (exercise then immediate sale) is a cashless-style outcome — proceeds from the sale cover the exercise cost.

Key Details

• Transaction date: 2026-06-26; Form 4 filed 2026-06-30.
• Exercise: 26,000 shares at $60.89 (total $1,583,140).
• Sale: 26,000 shares at weighted avg $81.05 (total $2,107,196); per-footnote sold under multiple trades priced $81.00–$81.34.
• Footnote F1: Shares sold pursuant to a Rule 10b5-1 trading plan adopted Nov 19, 2025. F2: weighted-average price disclosure; reporting person can provide per-trade breakdown on request.
• Shares owned after the transaction: not specified in the provided filing.
• No late-filing flag noted in the summary data; filing date is 2026-06-30 for the 2026-06-26 transactions.

Context

• The pattern (exercise followed by immediate sale under a 10b5-1 plan) is commonly used to monetize option gains while adhering to predetermined trading rules; it should not be read as a directional market prediction.
• For retail investors, purchases (insider buys) often carry more signal value than routine option exercises and sales; this filing documents monetization of existing option holdings.